Certara, Inc. (CERT)
Price:
8.57 USD
( - -0.23 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Privia Health Group, Inc.
VALUE SCORE:
8
2nd position
HealthEquity, Inc.
VALUE SCORE:
8
The best
Progyny, Inc.
VALUE SCORE:
9
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
DESCRIPTION
Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
NEWS
Certara Appoints Jon Resnick as Chief Executive Officer
globenewswire.com
2025-12-11 06:00:00Resnick brings decades of leadership experience in health sciences, business operations, strategy, innovation and commercial growth
Earnings Estimates Moving Higher for Certara (CERT): Time to Buy?
zacks.com
2025-12-08 13:21:05Certara, Inc. (CERT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Wall Street Analysts Think Certara (CERT) Could Surge 43.28%: Read This Before Placing a Bet
zacks.com
2025-12-08 10:55:22The average of price targets set by Wall Street analysts indicates a potential upside of 43.3% in Certara (CERT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Cerrado Gold Inc. (CERT:CA) Q3 2025 Earnings Call Transcript
seekingalpha.com
2025-12-01 17:13:24Cerrado Gold Inc. (CERT:CA) Q3 2025 Earnings Call Transcript
Intech Investment Management LLC Makes New $329,000 Investment in Certara, Inc. $CERT
defenseworld.net
2025-12-01 04:46:51Intech Investment Management LLC bought a new stake in Certara, Inc. (NASDAQ: CERT) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 28,147 shares of the company's stock, valued at approximately $329,000. Several other large investors have also recently
Touchstone Small Company Fund Q3 2025 Performance Review
seekingalpha.com
2025-11-27 09:30:00The Touchstone Small Company Fund underperformed its benchmark, the Russell 2000 Index, for the quarter ended September 30, 2025. Among the Fund's top-performing sectors in terms of adding value were Financials and Consumer Staples. From a factor perspective, the Fund's focus on profitable, liquid, and higher quality small cap stocks negatively impacted relative performance during the quarter.
Certara, Inc. (CERT) Presents at Stephens Annual Investment Conference 2025 Transcript
seekingalpha.com
2025-11-18 16:48:48Certara, Inc. ( CERT ) Stephens Annual Investment Conference 2025 November 18, 2025 2:00 PM EST Company Participants John Gallagher - SVP, Principal Accounting Officer & Chief Financial Officer Conference Call Participants Jeffrey Garro - Stephens Inc., Research Division Presentation Jeffrey Garro Stephens Inc., Research Division I think we're at the top of the hour, so we'll kick it off. A big thank you to John Gallagher, CFO of Certara, for joining us today at the Stephens Investment Conference in Nashville.
Certara, Inc. (CERT) Presents at Jefferies London Healthcare Conference 2025 Transcript
seekingalpha.com
2025-11-18 07:38:45Certara, Inc. ( CERT ) Jefferies London Healthcare Conference 2025 November 18, 2025 5:30 AM EST Company Participants William Feehery - CEO & Director Conference Call Participants David Windley - Jefferies LLC, Research Division Presentation David Windley Jefferies LLC, Research Division Okay. Good morning, everybody.
Certara, Inc. (CERT) Q3 2025 Earnings Call Transcript
seekingalpha.com
2025-11-06 20:56:08Certara, Inc. ( CERT ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants William Feehery - CEO & Director John Gallagher - SVP, Principal Accounting Officer & Chief Financial Officer Conference Call Participants David Deuchler - Gilmartin Group LLC Daniel Christopher Clark - Leerink Partners LLC, Research Division David Windley - Jefferies LLC, Research Division Matthew Hewitt - Craig-Hallum Capital Group LLC, Research Division Brendan Smith - TD Cowen, Research Division Joseph Vruwink - Robert W. Baird & Co. Incorporated, Research Division Kyle Crews - UBS Investment Bank, Research Division Max Smock - William Blair & Company L.L.C.
Certara, Inc. (CERT) Q3 Earnings Surpass Estimates
zacks.com
2025-11-06 19:55:52Certara, Inc. (CERT) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.13 per share a year ago.
Certara Reports Third Quarter 2025 Financial Results
globenewswire.com
2025-11-06 16:15:00RADNOR, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the third quarter of fiscal year 2025.
Certara Automates Scientific Workflows with Phoenix® Cloud
globenewswire.com
2025-11-04 08:00:00RADNOR, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of TFL Studio, the first cloud-native module of its Phoenix Cloud solution.
Certara to Participate in Upcoming Investor Conferences
globenewswire.com
2025-10-31 08:00:00RADNOR, Pa., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences:
Certara Expands Biosimulation Market with AI-Driven QSP Platform
globenewswire.com
2025-10-30 16:15:00RADNOR, Pa., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of Certara IQ, a scalable, AI-powered Quantitative Systems Pharmacology (QSP) solution.
Analysts Estimate Certara, Inc. (CERT) to Report a Decline in Earnings: What to Look Out for
zacks.com
2025-10-30 11:07:02Certara (CERT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Certara Scientists are Among the Topmost Cited Biopharma Researchers
globenewswire.com
2025-10-20 08:00:00RADNOR, Pa., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced its continued influence in pharmaceutical research.
No data to display
Certara Appoints Jon Resnick as Chief Executive Officer
globenewswire.com
2025-12-11 06:00:00Resnick brings decades of leadership experience in health sciences, business operations, strategy, innovation and commercial growth
Earnings Estimates Moving Higher for Certara (CERT): Time to Buy?
zacks.com
2025-12-08 13:21:05Certara, Inc. (CERT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Wall Street Analysts Think Certara (CERT) Could Surge 43.28%: Read This Before Placing a Bet
zacks.com
2025-12-08 10:55:22The average of price targets set by Wall Street analysts indicates a potential upside of 43.3% in Certara (CERT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Cerrado Gold Inc. (CERT:CA) Q3 2025 Earnings Call Transcript
seekingalpha.com
2025-12-01 17:13:24Cerrado Gold Inc. (CERT:CA) Q3 2025 Earnings Call Transcript
Intech Investment Management LLC Makes New $329,000 Investment in Certara, Inc. $CERT
defenseworld.net
2025-12-01 04:46:51Intech Investment Management LLC bought a new stake in Certara, Inc. (NASDAQ: CERT) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 28,147 shares of the company's stock, valued at approximately $329,000. Several other large investors have also recently
Touchstone Small Company Fund Q3 2025 Performance Review
seekingalpha.com
2025-11-27 09:30:00The Touchstone Small Company Fund underperformed its benchmark, the Russell 2000 Index, for the quarter ended September 30, 2025. Among the Fund's top-performing sectors in terms of adding value were Financials and Consumer Staples. From a factor perspective, the Fund's focus on profitable, liquid, and higher quality small cap stocks negatively impacted relative performance during the quarter.
Certara, Inc. (CERT) Presents at Stephens Annual Investment Conference 2025 Transcript
seekingalpha.com
2025-11-18 16:48:48Certara, Inc. ( CERT ) Stephens Annual Investment Conference 2025 November 18, 2025 2:00 PM EST Company Participants John Gallagher - SVP, Principal Accounting Officer & Chief Financial Officer Conference Call Participants Jeffrey Garro - Stephens Inc., Research Division Presentation Jeffrey Garro Stephens Inc., Research Division I think we're at the top of the hour, so we'll kick it off. A big thank you to John Gallagher, CFO of Certara, for joining us today at the Stephens Investment Conference in Nashville.
Certara, Inc. (CERT) Presents at Jefferies London Healthcare Conference 2025 Transcript
seekingalpha.com
2025-11-18 07:38:45Certara, Inc. ( CERT ) Jefferies London Healthcare Conference 2025 November 18, 2025 5:30 AM EST Company Participants William Feehery - CEO & Director Conference Call Participants David Windley - Jefferies LLC, Research Division Presentation David Windley Jefferies LLC, Research Division Okay. Good morning, everybody.
Certara, Inc. (CERT) Q3 2025 Earnings Call Transcript
seekingalpha.com
2025-11-06 20:56:08Certara, Inc. ( CERT ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants William Feehery - CEO & Director John Gallagher - SVP, Principal Accounting Officer & Chief Financial Officer Conference Call Participants David Deuchler - Gilmartin Group LLC Daniel Christopher Clark - Leerink Partners LLC, Research Division David Windley - Jefferies LLC, Research Division Matthew Hewitt - Craig-Hallum Capital Group LLC, Research Division Brendan Smith - TD Cowen, Research Division Joseph Vruwink - Robert W. Baird & Co. Incorporated, Research Division Kyle Crews - UBS Investment Bank, Research Division Max Smock - William Blair & Company L.L.C.
Certara, Inc. (CERT) Q3 Earnings Surpass Estimates
zacks.com
2025-11-06 19:55:52Certara, Inc. (CERT) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.13 per share a year ago.
Certara Reports Third Quarter 2025 Financial Results
globenewswire.com
2025-11-06 16:15:00RADNOR, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the third quarter of fiscal year 2025.
Certara Automates Scientific Workflows with Phoenix® Cloud
globenewswire.com
2025-11-04 08:00:00RADNOR, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of TFL Studio, the first cloud-native module of its Phoenix Cloud solution.
Certara to Participate in Upcoming Investor Conferences
globenewswire.com
2025-10-31 08:00:00RADNOR, Pa., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences:
Certara Expands Biosimulation Market with AI-Driven QSP Platform
globenewswire.com
2025-10-30 16:15:00RADNOR, Pa., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of Certara IQ, a scalable, AI-powered Quantitative Systems Pharmacology (QSP) solution.
Analysts Estimate Certara, Inc. (CERT) to Report a Decline in Earnings: What to Look Out for
zacks.com
2025-10-30 11:07:02Certara (CERT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Certara Scientists are Among the Topmost Cited Biopharma Researchers
globenewswire.com
2025-10-20 08:00:00RADNOR, Pa., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced its continued influence in pharmaceutical research.